KemPharm, Inc. (KMPH) Announces Quarterly Earnings Results, Beats Estimates By $0.19 EPS
KemPharm, Inc. (NASDAQ:KMPH) issued its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.19, Bloomberg Earnings reports.
Shares of KemPharm (KMPH) traded up 6.67% during midday trading on Friday, hitting $3.20. 54,016 shares of the stock were exchanged. The firm’s 50-day moving average is $3.48 and its 200 day moving average is $3.92. KemPharm has a 52-week low of $2.90 and a 52-week high of $5.50. The firm’s market cap is $46.87 million.
In other KemPharm news, CEO Travis C. Mickle bought 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The stock was purchased at an average cost of $3.45 per share, with a total value of $27,600.00. Following the completion of the acquisition, the chief executive officer now owns 1,629,612 shares in the company, valued at approximately $5,622,161.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders purchased 10,775 shares of company stock valued at $38,783. 22.80% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its position in KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 3,414 shares during the period. Victory Capital Management Inc. acquired a new position in KemPharm during the first quarter worth $647,000. C WorldWide Group Holding A S raised its position in KemPharm by 10.1% in the first quarter. C WorldWide Group Holding A S now owns 181,699 shares of the specialty pharmaceutical company’s stock worth $890,000 after buying an additional 16,699 shares during the period. Finally, Creative Planning raised its position in KemPharm by 2.3% in the first quarter. Creative Planning now owns 453,723 shares of the specialty pharmaceutical company’s stock worth $2,223,000 after buying an additional 10,200 shares during the period. 42.27% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently commented on KMPH shares. Roth Capital assumed coverage on shares of KemPharm in a research note on Wednesday, June 28th. They set a “buy” rating and a $8.00 price objective for the company. Oppenheimer Holdings, Inc. set a $13.00 price target on shares of KemPharm and gave the stock a “buy” rating in a research note on Thursday. Canaccord Genuity set a $7.00 price target on shares of KemPharm and gave the stock a “buy” rating in a research note on Thursday. Royal Bank Of Canada reissued a “buy” rating and issued a $8.00 price target on shares of KemPharm in a research note on Monday, May 15th. Finally, Zacks Investment Research raised shares of KemPharm from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research note on Thursday, May 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $8.10.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/11/kempharm-inc-kmph-announces-quarterly-earnings-results-beats-estimates-by-0-19-eps.html.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.